Angiotensin II and α-agonist. II. Effects on ovine fetoplacental prostaglandins

T. Yoshimura, R. R. Magness, C. R. Rosenfeld

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The fetoplacental vasculature is more sensitive to angiotensin II (ANG II) than to α-agonists, possibly reflecting their differing effects on vascular prostaglandin (PG) production. To examine this we studied in fetal sheep (123-138 days) the effects of ANG II (n = 7; 0.057, 1.15, and 5.73 μg/min) and phenylephrine (PHEN, n = 7; 0.306, 1.53, and 7.64 μg/min) on mean arterial pressure (MAP), heart rate (HR), and simultaneous measurements of umbilical arterial and venous PGE2, 6-keto-PGF(1α) (PGI2) and thromboxane B2 (TxB2) concentrations. ANG II increased MAP and decreased HR dose dependently (P<0.05). Basal umbilical venous plasma PGE2 levels exceeded PGI2 (P<0.001) and increased during ANG II infusions from 502 ± 63 to 516 ± 113,647 ± 188, and 1,968 ± 541 pg/ml (mean ±SE, P<0.05), as did venous-arterial concentration differences (129 ± 26 to 179 ± 47, 244 ± 58, and 1,287 ± 507 pg/ml, respectively; P<0.05). ANG II also increased umbilical venous PGI2 levels from 110 ± 13 to 116 ± 24, 144 ± 46, and 680 ± 147 pg/ml (P<0.01) and the venous-arterial concentration difference from 3 ± 6 to 20 ± 16, 41 ± 27, and 405 ± 122 pg/ml (P<0.05), respectively. ANG II had no effect on plasma TxB2, and no umbilical venous-arterial concentration differences existed. Although PHEN increased MAP and decreased HR, plasma eicosanoid concentrations were unaltered. The fetus is more sensitive to ANG II than PHEN; however, only ANG II increased placental PGE2 and PGI2 production. It is unlikely that local prostanoid production explains the observed refractoriness to α-adrenergic stimulation.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume259
Issue number2 28-2
StatePublished - 1990

Fingerprint

Angiotensin II
Prostaglandins
Sheep
Umbilicus
Epoprostenol
Dinoprostone
Thromboxane B2
Arterial Pressure
Heart Rate
Eicosanoids
Prostaglandins F
Phenylephrine
Adrenergic Agents
Blood Vessels
Fetus

Keywords

  • phenylephrine
  • placenta
  • pregnancy
  • prostacyclin
  • prostaglandi n E
  • thromboxane

ASJC Scopus subject areas

  • Physiology

Cite this

Angiotensin II and α-agonist. II. Effects on ovine fetoplacental prostaglandins. / Yoshimura, T.; Magness, R. R.; Rosenfeld, C. R.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 259, No. 2 28-2, 1990.

Research output: Contribution to journalArticle

@article{60ccb41c7a724785a16951ecb8ef6e02,
title = "Angiotensin II and α-agonist. II. Effects on ovine fetoplacental prostaglandins",
abstract = "The fetoplacental vasculature is more sensitive to angiotensin II (ANG II) than to α-agonists, possibly reflecting their differing effects on vascular prostaglandin (PG) production. To examine this we studied in fetal sheep (123-138 days) the effects of ANG II (n = 7; 0.057, 1.15, and 5.73 μg/min) and phenylephrine (PHEN, n = 7; 0.306, 1.53, and 7.64 μg/min) on mean arterial pressure (MAP), heart rate (HR), and simultaneous measurements of umbilical arterial and venous PGE2, 6-keto-PGF(1α) (PGI2) and thromboxane B2 (TxB2) concentrations. ANG II increased MAP and decreased HR dose dependently (P<0.05). Basal umbilical venous plasma PGE2 levels exceeded PGI2 (P<0.001) and increased during ANG II infusions from 502 ± 63 to 516 ± 113,647 ± 188, and 1,968 ± 541 pg/ml (mean ±SE, P<0.05), as did venous-arterial concentration differences (129 ± 26 to 179 ± 47, 244 ± 58, and 1,287 ± 507 pg/ml, respectively; P<0.05). ANG II also increased umbilical venous PGI2 levels from 110 ± 13 to 116 ± 24, 144 ± 46, and 680 ± 147 pg/ml (P<0.01) and the venous-arterial concentration difference from 3 ± 6 to 20 ± 16, 41 ± 27, and 405 ± 122 pg/ml (P<0.05), respectively. ANG II had no effect on plasma TxB2, and no umbilical venous-arterial concentration differences existed. Although PHEN increased MAP and decreased HR, plasma eicosanoid concentrations were unaltered. The fetus is more sensitive to ANG II than PHEN; however, only ANG II increased placental PGE2 and PGI2 production. It is unlikely that local prostanoid production explains the observed refractoriness to α-adrenergic stimulation.",
keywords = "phenylephrine, placenta, pregnancy, prostacyclin, prostaglandi n E, thromboxane",
author = "T. Yoshimura and Magness, {R. R.} and Rosenfeld, {C. R.}",
year = "1990",
language = "English (US)",
volume = "259",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "2 28-2",

}

TY - JOUR

T1 - Angiotensin II and α-agonist. II. Effects on ovine fetoplacental prostaglandins

AU - Yoshimura, T.

AU - Magness, R. R.

AU - Rosenfeld, C. R.

PY - 1990

Y1 - 1990

N2 - The fetoplacental vasculature is more sensitive to angiotensin II (ANG II) than to α-agonists, possibly reflecting their differing effects on vascular prostaglandin (PG) production. To examine this we studied in fetal sheep (123-138 days) the effects of ANG II (n = 7; 0.057, 1.15, and 5.73 μg/min) and phenylephrine (PHEN, n = 7; 0.306, 1.53, and 7.64 μg/min) on mean arterial pressure (MAP), heart rate (HR), and simultaneous measurements of umbilical arterial and venous PGE2, 6-keto-PGF(1α) (PGI2) and thromboxane B2 (TxB2) concentrations. ANG II increased MAP and decreased HR dose dependently (P<0.05). Basal umbilical venous plasma PGE2 levels exceeded PGI2 (P<0.001) and increased during ANG II infusions from 502 ± 63 to 516 ± 113,647 ± 188, and 1,968 ± 541 pg/ml (mean ±SE, P<0.05), as did venous-arterial concentration differences (129 ± 26 to 179 ± 47, 244 ± 58, and 1,287 ± 507 pg/ml, respectively; P<0.05). ANG II also increased umbilical venous PGI2 levels from 110 ± 13 to 116 ± 24, 144 ± 46, and 680 ± 147 pg/ml (P<0.01) and the venous-arterial concentration difference from 3 ± 6 to 20 ± 16, 41 ± 27, and 405 ± 122 pg/ml (P<0.05), respectively. ANG II had no effect on plasma TxB2, and no umbilical venous-arterial concentration differences existed. Although PHEN increased MAP and decreased HR, plasma eicosanoid concentrations were unaltered. The fetus is more sensitive to ANG II than PHEN; however, only ANG II increased placental PGE2 and PGI2 production. It is unlikely that local prostanoid production explains the observed refractoriness to α-adrenergic stimulation.

AB - The fetoplacental vasculature is more sensitive to angiotensin II (ANG II) than to α-agonists, possibly reflecting their differing effects on vascular prostaglandin (PG) production. To examine this we studied in fetal sheep (123-138 days) the effects of ANG II (n = 7; 0.057, 1.15, and 5.73 μg/min) and phenylephrine (PHEN, n = 7; 0.306, 1.53, and 7.64 μg/min) on mean arterial pressure (MAP), heart rate (HR), and simultaneous measurements of umbilical arterial and venous PGE2, 6-keto-PGF(1α) (PGI2) and thromboxane B2 (TxB2) concentrations. ANG II increased MAP and decreased HR dose dependently (P<0.05). Basal umbilical venous plasma PGE2 levels exceeded PGI2 (P<0.001) and increased during ANG II infusions from 502 ± 63 to 516 ± 113,647 ± 188, and 1,968 ± 541 pg/ml (mean ±SE, P<0.05), as did venous-arterial concentration differences (129 ± 26 to 179 ± 47, 244 ± 58, and 1,287 ± 507 pg/ml, respectively; P<0.05). ANG II also increased umbilical venous PGI2 levels from 110 ± 13 to 116 ± 24, 144 ± 46, and 680 ± 147 pg/ml (P<0.01) and the venous-arterial concentration difference from 3 ± 6 to 20 ± 16, 41 ± 27, and 405 ± 122 pg/ml (P<0.05), respectively. ANG II had no effect on plasma TxB2, and no umbilical venous-arterial concentration differences existed. Although PHEN increased MAP and decreased HR, plasma eicosanoid concentrations were unaltered. The fetus is more sensitive to ANG II than PHEN; however, only ANG II increased placental PGE2 and PGI2 production. It is unlikely that local prostanoid production explains the observed refractoriness to α-adrenergic stimulation.

KW - phenylephrine

KW - placenta

KW - pregnancy

KW - prostacyclin

KW - prostaglandi n E

KW - thromboxane

UR - http://www.scopus.com/inward/record.url?scp=0025004365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025004365&partnerID=8YFLogxK

M3 - Article

VL - 259

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 2 28-2

ER -